Kura Oncology Valuation
| KURA Stock | USD 6.60 0.22 3.45% |
At this time, the firm appears to be undervalued. Kura Oncology secures a last-minute Real Value of $11.13 per share. The latest price of the firm is $6.6. Our model forecasts the value of Kura Oncology from analyzing the firm fundamentals such as Profit Margin of (2.68) %, return on equity of -0.42, and Current Valuation of (108.13 M) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Kura Oncology's valuation include:
Price Book 1.4564 | Enterprise Value | Enterprise Value Ebitda (2.48) | Price Sales 8.404 | Enterprise Value Revenue 3.0004 |
Undervalued
Today
Please note that Kura Oncology's price fluctuation is somewhat reliable at this time. Calculation of the real value of Kura Oncology is based on 3 months time horizon. Increasing Kura Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kura Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kura Stock. However, Kura Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.6 | Real 11.13 | Target 25.92 | Hype 6.6 | Naive 7.4 |
The real value of Kura Stock, also known as its intrinsic value, is the underlying worth of Kura Oncology Company, which is reflected in its stock price. It is based on Kura Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kura Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kura Oncology helps investors to forecast how Kura stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kura Oncology more accurately as focusing exclusively on Kura Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kura Oncology's intrinsic value based on its ongoing forecasts of Kura Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kura Oncology's closest peers. If more than one evaluation category is relevant for Kura Oncology we suggest using both methods to arrive at a better estimate.
Kura Oncology Cash |
|
Kura Valuation Trend
Comparing Kura Oncology's enterprise value against its market capitalization is a good way to estimate the value of Kura Oncology uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Kura Oncology Total Value Analysis
Kura Oncology is now projected to have valuation of (108.13 M) with market capitalization of 571.39 M, debt of 16.59 M, and cash on hands of 450.26 M. The negative valuation of Kura Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Kura Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(108.13 M) | 571.39 M | 16.59 M | 450.26 M |
Kura Oncology Investor Information
About 94.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kura Oncology recorded a loss per share of 2.16. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Kura Oncology's financial statements, Kura Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August.Kura Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kura Oncology has an asset utilization ratio of 7.09 percent. This suggests that the Company is making $0.0709 for each dollar of assets. An increasing asset utilization means that Kura Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Kura Oncology Ownership Allocation
Kura Oncology maintains a total of 86.57 Million outstanding shares. The majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kura Oncology Profitability Analysis
The company reported the previous year's revenue of 53.88 M. Net Loss for the year was (173.98 M) with loss before overhead, payroll, taxes, and interest of (107.06 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kura Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kura Oncology and how it compares across the competition.
About Kura Oncology Valuation
The stock valuation mechanism determines Kura Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Kura Oncology. We calculate exposure to Kura Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kura Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 53 M | 55.7 M | |
| Pretax Profit Margin | (2.87) | (3.02) | |
| Operating Profit Margin | (3.23) | (3.39) | |
| Net Loss | (2.91) | (3.05) | |
| Gross Profit Margin | 0.89 | 0.78 |
Kura Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 86.2 M |
Kura Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Kura Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kura we look at many different elements of the entity such as Kura's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Kura Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Kura Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Kura Oncology's worth.Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |